Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Immutep S.A.S.
Sydney, New South Wales, Australiaimmutep.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Other
01
Overview
Immutep’s lead candidate, eftilagimod alpha (efti), is in a pivotal Phase 3 trial in first-line non-small cell lung cancer in combination with pembrolizumab and chemotherapy; multiple Phase 2 and earlier trials in various solid tumors and autoimmune diseases are ongoing. The company has licensed out certain LAG-3 pipeline assets to major pharma partners with external programs in both oncology and autoimmune diseases. Efti has shown improved response rates and robust safety in several completed and ongoing studies.[1][4][2]
- Therapeutic areas
- OncologyImmunology
- Modalities
- Recombinant fusion proteinMonoclonal antibody
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on Immutep S.A.S..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immutep S.A.S..